menu search

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
— Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 — — Phase 3 SYNCHRONY studies on track to begin enrolling in the second half of 2023 […] The post Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update appeared first on ForexTV... Read More
Posted: Aug 11 2023, 10:00
Author Name: forextv
Views: 022241

Search within

Pages Search Results: